Foresite Capital

www.foresitecapital.com

VCMatch tracks Foresite Capital as an investor focused on Biotech, Medtech, and Digital Health companies, Pre-Seed and Seed rounds, and United States markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage

Focus Areas

Biotech, Medtech, Digital Health

Geography

United States

Investment Thesis

Foresite Capital invests at the intersection of biology and big data, targeting companies that ‘‘leverage biology and big data to transform healthcare.’’ They pursue a hands-on, research-driven approach—combining investment analysts, MD/PhDs and data scientists—to discover and build category-transforming healthcare companies, and they partner with companies across the entire lifecycle (‘‘from incubation to IPO and beyond’’). Their stated intent is to deploy capital, technical expertise and networks to help build transformative healthcare companies and ‘‘significantly impact the quality and effectiveness of the U.S. healthcare system.’’

Is Foresite Capital right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Foresite Capital is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Medtech, Digital Health, and Pharma, especially across United States.

Focus statement

‘‘We focus on the forces driving healthcare transformation, and breakthrough companies that seek to transform their category.’’ In particular they invest in ‘‘people, ideas and discoveries marrying tech and biotech to personalize healthcare and accelerate innovation and product development.’’

Value Add

Data-science orientation: explicitly claims ‘‘We use a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare.’’
Cross-disciplinary internal team: emphasizes that ‘‘Our team of investment analysts, MD/PhDs and data scientists work closely with each company we invest in.’’
Full-lifecycle support: branded as ‘‘Full Lifecycle Investing’’ and states ‘‘We partner at all stages – from incubation to IPO and beyond. Our goal is to have impact regardless of timing.’’
Deep scientific diligence capability: built an internal ‘‘research and development evaluation group’’ and highlights rigorous review of scientific validation, clinical efficacy/safety, manufacturing readiness and regulatory risk (described in Dorothy Margolskee’s role).
Founder/operator pedigree and track record: founder Jim Tananbaum frames the firm around merging computational and biological expertise and has a long track record founding and scaling healthcare companies, which the firm leverages in sourcing and supporting deals.
Extensive ecosystem network: promotes ‘‘friends, partners and former colleagues throughout the healthcare ecosystem’’ to support portfolio companies.
Sector breadth within healthcare-tech/biotech: invests across therapeutics, devices, diagnostics and services and lists a large, varied portfolio (e.g., Affinivax, 10x Genomics, Insitro, GRAIL).